GGDPS Inhibitors

Small molecule inhibitors of GGDPS provide new treatment approach for cancer

  • Small molecule inhibitors of GGDPS
  • Nanomolar potency
  • Novel treatment approach for multiple myeloma and other cancers

 
Licensing manager: Matt Boehm, Ph.D.
mboehm@unmc.edu or 402-559-2166
 

SKU: 464 Category: Tags: , ,

Description

Small molecule inhibitors of GGDPS provide new treatment approach for cancer

Researchers at the University of Nebraska Medical Center and the University of Iowa have teamed up to develop new drugs to help treat multiple myeloma and other types of cancer.
 
The new drugs target a protein called geranylgeranyl diphosphate synthase, also known as GGDPS.
 
GGDPS is involved in the regulation of the Rab family of small but important proteins that are also often linked to cancer: GTPases. Targeting GGDPS may provide a way to inhibit Rab family proteins, providing a unique way to treat various forms of cancer.
 
The new GGDPS inhibitors have nanomolar potency and are being assessed in vivo to determine pharmacokinetics properties and efficacy.
 
To discuss licensing opportunities contact Matt Boehm, Ph.D., at mboehm@unmc.edu or 402-559-2166.
 

Additional Info

Publications

Intellectual Property

  • PCT patent application filed